- Home
- XAIR vs TCRT Comparison
XAIR vs TCRT Comparison
Compare XAIR & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | TCRT |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.3M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | XAIR | TCRT |
|---|---|---|
| Price | $5.50 | $2.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 234.9K | 12.2K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | N/A | ★ N/A |
| Revenue | $7,679,000.00 | ★ $15,900,000.00 |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $1.67 |
| 52 Week High | $8.19 | $4.57 |
Technical Indicators
Market Signals| Indicator | XAIR | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 76.75 | 42.34 |
| Support Level | $0.64 | $1.95 |
| Resistance Level | N/A | $2.43 |
| Average True Range (ATR) | 0.33 | 0.11 |
| MACD | 0.60 | 0.01 |
| Stochastic Oscillator | 68.12 | 16.00 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.